Future studies will determine the mechanism by which PSMD1 or PSMD3 are upregulated in CML and other types of cancers, and will interrogate their potential as novel therapeutic targets. This evidence concerns the gene PSMD3 and chronic myelogenous leukemia, BCR-ABL1 positive.